BiondVax Pharmaceuticals Ltd. (BVXV)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0700 |
| Open | 1.0700 |
| Bid | 0.9400 x 1000 |
| Ask | 1.0200 x 1300 |
| Day's Range | 0.9402 - 1.1000 |
| 52 Week Range | 0.8880 - 3.4900 |
| Volume | |
| Avg. Volume | 53,969 |
| Market Cap | 18.677M |
| Beta (5Y Monthly) | 2.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2960 |
| Earnings Date | May 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BVXV
Related Research
- BiondVax Pharmaceuticals Ltd.CARA: Lowering target price to $11.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat10 months agoArgus Research
- Zacks Small Cap Research
BVXV: Results for Preclinical Inhalation Proof-of-Concept Study in COVID-19 Expected by End of This Year…
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update NanoAb Program Advancing on Schedule BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is developing alpaca-derived nanosized antibodies (NanoAbs), with an initial program focused on anti-SARS-CoV-2 NanoAbs. The company signed definitive agreements with the Max Plank Institute for Multidisciplinary Sciences and the
- PR Newswire
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today provided encouraging updates related to the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences (MPG), and the University Medical Center Göttingen (UMG) towards the development of a pipeline of innovative alpaca–derived nanosized ant
- PR Newswire
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that the company's Chief Executive Officer, Mr. Amir Reichman, will attend the H.C. Wainwright 24th Annual Global Investment Conference in–person, and his pre–recorded presentation will be available during the conference via the online conference portal a
